Mark Uhle

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

DSM BV engages in the provision of ingredients, expertise, and solutions for plant-based products. It operates through the following segments: Animal Nutrition and Health (ANH); Health, Nutrition, and Care (HNC); Food and Beverage (F and B); and Other. The ANH segment includes developing sustainable animal farming through essential products, performance solutions, and precision services serving the poultry, swine, ruminants, and aquaculture markets. The HNC segment provides health, nutrition, and care solutions for markets such as early life nutrition, dietary supplements, pharma, medical, and personal care. The F and B segment focuses on supporting healthy diets through nutritious, delicious, and sustainable solutions for several market segments including bakery, beverages and brewing, dairy, savory, plant-based alternative proteins, and pet food. The Other segment is involved in corporate activities. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands.

University of Washington functions as a College/University. The company is headquartered in Seattle, WA.

Evonik Corp. manufactures specialty chemicals. It manufactures coatings and advanced fillers, construction chemicals, fine & industrial chemicals, performance materials and specialty polymers. The company's products range from sports and industrial floorings to amino acids and building protection coatings. Evonik is headquartered in Parsippany, NJ.

Part of Innocoll Holdings Plc, Syntacoll GmbH is a German pharmaceutical company that develops and manufactures fully resorbable collagen-based implants. The company is based in Saal an der Donau, Germany and was founded in 1992. The CEOs are Alexandra Dietrich and Kimball Hall. Syntacoll is the only development and production site of Innocoll, and their products are manufactured according to GMP and ISO 13485 standards. The company holds a manufacturing license for active substance-containing drugs based on collagen. Syntacoll's mission is to provide innovative medical and pharmaceutical products for patient care, and their vision is to be recognized as one of the leading providers of medical and pharmaceutical products worldwide. The company values integrity, inclusion, collaboration, and responsibility.